Technikfolgenabschätzung des CRISPR/Cas-Systems

Since the description of the CRISPR/Cas System as a potential gene splicer in 2012, the idea of precise alteration of the genome in human germ cells and embryos has seemed to come within reach. This book provides a profound risk-benefit presentation that considers both individual and societal aspects and offers a differentiated presentation of competing positions in the debate about this controversial intervention.